pharmaphorum

AUGUST 8, 2022

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing.

Marketing 111

Marketing Sales Gene Editing Antibody 111

Pharmaceutical Technology

MARCH 1, 2023

Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

JANUARY 19, 2023

However, it is possible to target CD33 in the clinic, as evidenced by the FDA approval of Pfizer’s anti-CD33 antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin) in 2000. The first clinical attempt at managing AML with CAR-T cells was reported in 2013 with a small Phase I study that did not demonstrate activity.

Marketing 130

Marketing Gene Editing Production Sales 130

XTalks

OCTOBER 12, 2021

They found that removal of the protein using gene editing technology led to severe early onset arthritis as well as bone loss in two rat models. antibodies in the knockout (KO) rats. In rescue experiments, supplementation of the antibodies through passive immunization did not suppress arthritis. KO animals.

Vaccine 105

Vaccine Vaccination Research Immune Response 105

pharmaphorum

JULY 13, 2021

The Danish drugmaker is paying $100 million upfront for rights to antibody drug PRX004, which is heading for phase 2 trials in cardiomyopathy associated with ATTR amyloidosis, a life-threatening disease affecting the heart and nervous system. The post Novo Nordisk bulks up in rare diseases with $1.2bn Prothena deal appeared first on.

Gene Silencing 98

Gene Silencing Sales Gene Editing Clinical Trials 98

Worldwide Clinical Trials

MAY 30, 2024

Additional research is underway using gene editing via CRISPR, primarily investigating genes with known relationships to ALS, such as SOD1 and C9orf72. However, work is needed before CRISPR-mediated treatments become possible, including a better understanding of the genes involved in ALS.

Gene 204

Gene Clinical Trials Clinical Trials Gene Therapy 204

The Pharma Data

DECEMBER 11, 2020

of Children’s Hospital at TriStar Centennial in Nashville, Tennessee, and colleagues found that gene editing using CRISPR-Cas9 is safe and feasible and can provide clinical benefit to patients with sickle cell disease and transfusion-dependent ß-thalassemia. ASH: CRISPR-Cas9 Gene Editing Promising in TDT, SCD.

Gene Editing 52

Gene Editing Gene Gene Therapy In-Vivo 52

XTalks

JANUARY 4, 2024

The adeno-associated viral (AAV) vector-based gene therapy received approval in Canada for the treatment of adults aged 18 years or older with moderately-severe to severe hemophilia B who are negative for neutralizing antibodies to variant AAV serotype Rh74, Pfizer Canada revealed in its announcement of the approval.

Gene Therapy 111

Gene Therapy Gene Gene Editing Sales 111

pharmaphorum

JULY 1, 2021

Synthetic biology has grown exponentially in less than a decade, with CRISPR gene-editing as the key technology driving this through its use in areas like cancer, infectious diseases, and rare, undertreated indications. Here are my key takeaways from SynBioBeta’s conference.

Gene Editing 88

Gene Editing Engineer Development Gene 88

Delveinsight

AUGUST 27, 2020

As observed in 45 younger adults, the middle dose of the vaccine triggered the production of neutralizing antibodies against SARS-CoV-2, the virus, which causes COVID-19 , in 10 patients aged 56 to 70 and 10 patients over 71. Freenome secures USD 270 Million to boost its colorectal cancer blood test.

Vaccine 53

Vaccine Vaccination Research Trials 53

pharmaphorum

FEBRUARY 17, 2022

The pushback has also affected another new drug for SCD, Novartis’ antibody Adakveo (crizanlizumab), used to treat the painful vaso-occlusive crises (VOCs) that periodically afflict people with the disease, which has also been highlighted as a potential blockbuster.

Drugs 59

Drugs Gene Therapy Gene Editing Gene 59

The Pharma Data

JANUARY 24, 2021

. “We are excited to welcome Chris, a highly regarded drug developer and team builder who brings to Notch great depth of experience and expertise in development of cell therapies, gene editing, and cell engineering spanning discovery through IND,” said David Main , President and Chief Executive Officer of Notch.

Engineer 52

Engineer Gene Editing Genome Genomics 52

XTalks

NOVEMBER 30, 2023

These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV. In 2021, the FDA granted approval to San Francisco-based Excision BioTherapeutics to start trials assessing CRISPR gene editing as a potential treatment for HIV. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Cloudbyz

MARCH 6, 2024

For example, monoclonal antibodies, a type of biologic, can selectively bind to specific targets such as proteins or cells involved in disease processes, thereby modulating immune responses or inhibiting disease progression. One of the key features of biologics is their ability to mimic or augment natural biological processes within the body.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. for its cGMP-compliant CHOSOURCE platform. in Mainland China.

Drugs 52

Drugs Gene Editing Genomics Genome 52

XTalks

MARCH 28, 2024

Furthermore, the introduction of multi-targeted kinase inhibitors and monoclonal antibodies is also being examined as a possible form of therapy. Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

Delveinsight

MARCH 2, 2021

Toripalimab is the first domestic anti-PD-1 monoclonal antibody that received approval for marketing in China. As per the company, its manufacturing platform supports large-scale production and cryopreservation of off-the-shelf, allogeneic NK cell therapies and proprietary CAR-NK and NK-specific gene-editing technologies.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

The Pharma Data

JANUARY 24, 2021

All participants randomized to receive either 4,200 mg of bamlanivimab, Lilly’s neutralizing antibody, or placebo. CYAD-101 is the company’s allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR-T candidate. Non-COVID-19-Related. It is being administered together with FOLFOX chemotherapy.

Trials 52

Trials Allergies In-Vitro Antibody 52

XTalks

AUGUST 2, 2023

2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

NOVEMBER 3, 2020

LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies. Data presented have shown that the capsids deliver highly efficient functional transduction of human hepatocytes with improved manufacturability with low levels of pre-existing neutralizing antibodies in human samples.

Clinical Trials 40

Clinical Trials Clinical Trials Gene Editing Genome 40

Pharma Marketing Network

JANUARY 20, 2021

Perhaps this omission is because the systemically administered vaccines are unable to stimulate robust immune responses in the mucosae, despite generating systemic neutralizing antibody (and possibly T cell) responses. Analyses of this large dataset should help to identify prognostic biomarkers and support therapeutic development.

Vaccine 52

Vaccine Vaccination In-Vivo Genetics 52

The Pharma Data

DECEMBER 27, 2020

Notably, we never modify the DNA of these cells, which avoids some of the safety concerns that have been reported with certain gene-editing technologies. From these cells we apply proprietary methods to manufacture pure populations of only the cell types which we wish to use in patients.

Manufacturing 40

Manufacturing Production Development Clinical Trials 40

XTalks

DECEMBER 24, 2020

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. Antibody drugs were also developed as targeted COVID-19 treatments.

Life Science 111

Life Science Vaccine Vaccination Gene 111

Pharmaceutical Technology

MARCH 2, 2023

ImmunoGen has announced an agreement granting rights to Vertex Pharmaceuticals to carry out research using antibody-drug conjugate (ADC) technology for the discovery of new targeted conditioning agents. The research using ImmunoGen’s technology will enable the discovery of the agents for use with gene editing.

Gene Editing 130

Gene Editing Gene Development Research 130

Roots Analysis

JANUARY 27, 2025

It is important to note that, for the purpose of subcutaneous biologics market analysis, the biologics were segregated into antibodies , nucleotides, proteins and vaccines. Currently, antibodies segment is likely to occupy the largest share in the overall market. Further, majority of the approved subcutaneous biologics are proteins.

Marketing 40

Marketing Drug Delivery Development Protein 40